Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 95 plus docetaxel and prednisone in first-line metastatic hormone-refractory prostate cancer
2006-005766-39Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intetumumab in prostate cancer (PCa) (2 arms), sponsored by Janssen Biotech. Primary endpoint: Progression-free survival. Started Mar 2007; status: completed.
02
Drugs
intetumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-005766-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005766-39.